Bristol Myers, insitro ally to apply machine learning to ALS R&D

Bristol Myers Squibb has teamed up with insitro to develop treatments for neurodegenerative disorders. The deal is worth $50 million upfront but could balloon in value to more than $2 billion if all the milestones are hit.

Under the terms of the deal, insitro will use its platform to create induced pluripotent stem cell-derived disease models for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The platform uses machine learning, human genetics and functional genomics to generate in vitro models that shed light on disease progression and segment the patient population.